RCS - Envision Pharma Grp - Envision Pharma Group Announcement

IQVIA Holdings

08/04/2026 13:00

RNS Number : 5153Z

Envision Pharma Group

08 April 2026

 

Envision Pharma Group appoints Nick Jones as President, Envision Medical Communications

Seasoned technology and life sciences leader to advance AI integration across medical communications

FAIRFIELD, CT / ACCESS Newswire / April 8, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, today announced the appointment of Nick Jones as President, Envision Medical Communications (EMC). In this role, Jones will lead the EMC business, focusing on integrating Envision's industry-leading technology and AI capabilities into its award-winning portfolio of solutions and services.

Jones joins the company from ConcertAI, where he served as Senior Vice President and General Manager, Commercial Solutions, leading teams delivering consulting services, AI-driven software-as-a-service solutions, and data products supporting pharmaceutical commercialization.

Prior to ConcertAI, he spent over a decade at IQVIA (formerly IMS), leading technology and consulting organizations across the US, Europe, and JAPAC, delivering an integrated solutions portfolio spanning technology, consulting, real-world evidence, and analytics to global and mid-size pharma clients.

Jones will report directly to Tom Langan, CEO of Envision Pharma Group, and join Envision's Executive Leadership Team.

"Nick brings deep expertise, global market insight, and a shared ambition to build a world-class, tech-enabled pharma services organization," says Langan. "His broad experience in technology and consulting will benefit both Envision and our clients. This is yet another step in our evolution as we strive to execute with precision and exceed client expectations."

Jones adds, "Envision has consistently stood out in the pharma services industry for its credibility and excellence in medcomms. I am excited to join the company, and EMC in particular, as we build a market-leading, tech-enabled portfolio to meet the evolving needs of our pharma clients."

-Ends-

About Envision Pharma Group

Envision Pharma Group is a global, technology-enabled solutions partner to the life sciences industry. We harness the power of combined intelligence -human expertise and technology - to advance how scientific innovation translates into improved patient outcomes. We unite scientific expertise, strategic insight, and AI-powered tools to help clients create, communicate, and demonstrate value, accelerating access to life-changing treatments. With more than 20 years of experience and trusted partnerships with 400+ biopharma companies, including all top 20 pharma, we deliver integrated solutions across the product lifecycle, from medical communications to commercialization and compliance, through flexible models that scale to client needs. Together, we combine human insight and technology to drive smarter decisions, measurable impact, and sustainable growth.

Learn more: www.envisionpharmagroup.com

For more information, contact:

Sophie Berger, Global Head, Marketing, Envision Pharma Group

Email: sophie.berger@envisionpharma.com

Brittany Bowen, Media Relations, Geben Communication

Email: brittanybowen@gebencommunication.com

SOURCE: Envision Pharma Group

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRASSUFLWEMSEDL